Cedric Dos Santos
Global Product Leader AstraZeneca
Seminars
Thursday 5th February 2026
Panel Discussion: Accelerating the Use of MRD as a Surrogate Endpoint Across Indications
9:30 am
- Leveraging existing MRD evidence from hematology (e.g. multiple myeloma) to inform regulatory and policy pathways in new settings
- Driving alignment on assays, thresholds, endpoints, and timepoints to ensure cross-study comparability and reproducibility
- Building collaborative frameworks and secure data-sharing models to generate the robust evidence required by regulators and payers
Wednesday 4th February 2026
Building Standardized ctDNA & MRD Strategies to Accelerate Clinical Development of Immune-Based Therapies
5:15 pm
- Examining how ctDNA and MRD assays can serve as regulatory-acceptable biomarkers and support commercialization of CAR-T and T-cell engager therapies
- Addressing harmonization challenges across assay platforms and how standardization can streamline late-phase trials and companion diagnostic development
- Exploring opportunities for integrated, multi-omic bloodbased assays to provide scalable solutions that meet payer, regulatory, and clinician expectations
